Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Kailera Therapeutics

Kailera Therapeutics

Series BUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$600Msum of rounds with a disclosed amount only
Named investors
12
Financing history
1 rounds
  1. Oct 14, 2025
    Series B · $600M (disclosed)
    Bain Capital Private Equity (participant)Adage Capital Management (participant)Canada Pension Plan Investment Board (participant)Invus (participant)Perseverance Capital (participant)Qatar Investment Authority (participant)Royalty Pharma (participant)Surveyor Capital (participant)Atlas Venture (participant)Bain Capital Life Sciences (participant)RTW Investments (participant)Kailera (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity”
Investors on record
12 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Oct 14, 2025
    Kailera Therapeutics announced Series B of $600,000,000
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company